Combined treatment with sacubitril/valsartan plus dapagliflozin in patients affected by heart failure with reduced ejection fraction

BACKGROUND: Data about real-world effects of combined therapy with sacubitril/valsartan plus dapagliflozin in patients affected by heart failure (HF) with reduced ejection fraction (HFrEF) has not been widely reported. In this article, the benefits of dapagliflozin and sacubitril/valsartan respect t...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Juan, Gao, Jie, Zhang, Xiuzhen, Li, Yuanmin, Dang, Heqin, Liu, Yanlin, Chen, Wenwen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10073490/
https://www.ncbi.nlm.nih.gov/pubmed/37034349
http://dx.doi.org/10.3389/fcvm.2023.1097066

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10073490/
https://www.ncbi.nlm.nih.gov/pubmed/37034349
http://dx.doi.org/10.3389/fcvm.2023.1097066

Ejemplares similares